Serum EGFR and HER2 Levels in Breast Cancer
Author Information
Author(s): Asgeirsson Kristjan S, Agrawal Amit, Allen Claire, Hitch Anthony, Ellis Ian O, Chapman Caroline, Cheung Kwok L, Robertson John FR
Primary Institution: University of Nottingham
Hypothesis
The study aims to analyze serum expression of EGFR and HER2 in paired samples from primary and metastatic breast cancer patients.
Conclusion
Serum oncogene assessments may complement primary tumor evaluations and widen indications for targeted therapies.
Supporting Evidence
- Serum EGFR levels were significantly higher in healthy individuals than in primary breast cancer patients.
- EGFR levels decreased significantly from primary to metastatic diagnosis.
- HER2 levels increased significantly from primary to metastatic diagnosis.
- 32% of patients showed a change in HER2 expression from normal to over-expression.
Takeaway
This study found that levels of certain proteins in the blood change when breast cancer spreads, which might help doctors decide on treatments.
Methodology
Immunoassays for EGFR and HER2 were conducted on blood samples from breast cancer patients and healthy individuals.
Potential Biases
Potential selection bias due to the nature of patient recruitment and treatment history.
Limitations
The study had a small sample size for tissue analysis and relied on serum markers, which may not fully represent tumor biology.
Participant Demographics
Patients included 57 breast cancer patients with paired serum samples, aged 30 to 86 years, mean age 54 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website